21.44 USD
-0.08 (-0.37%)
Taking everything into account, SRPT scores 3 out of 10 in our fundamental rating. SRPT was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of SRPT have multiple concerns. SRPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRPT had negative earnings in the past year.
SRPT had a negative operating cash flow in the past year.
SRPT had negative earnings in 4 of the past 5 years.
In the past 5 years SRPT reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of SRPT (-7.77%) is better than 85.09% of its industry peers.
SRPT has a better Return On Equity (-20.57%) than 83.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SRPT (76.25%) is better than 84.15% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
Compared to 5 years ago, SRPT has more shares outstanding
SRPT has a better debt/assets ratio than last year.
2.2 Solvency
SRPT has an Altman-Z score of -0.01. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
SRPT has a Altman-Z score of -0.01. This is in the better half of the industry: SRPT outperforms 60.38% of its industry peers.
SRPT has a Debt/Equity ratio of 0.78. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
SRPT's Debt to Equity ratio of 0.78 is on the low side compared to the rest of the industry. SRPT is outperformed by 71.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.01 |
ROIC/WACCN/A
WACC7.46%
2.3 Liquidity
SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
SRPT has a Current ratio of 2.95. This is in the lower half of the industry: SRPT underperforms 64.72% of its industry peers.
A Quick Ratio of 1.79 indicates that SRPT should not have too much problems paying its short term obligations.
The Quick ratio of SRPT (1.79) is worse than 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for SRPT have decreased strongly by -197.60% in the last year.
The Revenue has grown by 47.15% in the past year. This is a very strong growth!
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
SRPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.74% yearly.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.76% yearly.
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.74%
Revenue Next Year13.31%
Revenue Next 2Y-8.22%
Revenue Next 3Y-7.29%
Revenue Next 5Y-5.76%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 9.13, the valuation of SRPT can be described as very reasonable.
98.68% of the companies in the same industry are more expensive than SRPT, based on the Price/Forward Earnings ratio.
SRPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.13 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as SRPT's earnings are expected to decrease with -6.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
5. Dividend
5.1 Amount
SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SRPT (1/2/2026, 12:32:09 PM)
21.44
-0.08 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.86%
Inst Owner Change1.89%
Ins Owners4.62%
Ins Owner Change19.41%
Market Cap2.25B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68.24
Price Target30.15 (40.62%)
Short Float %20.17%
Short Ratio4.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)-5.86%
PT rev (3m)-10.53%
EPS NQ rev (1m)2.17%
EPS NQ rev (3m)-34.86%
EPS NY rev (1m)-23.42%
EPS NY rev (3m)-20.97%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)8.32%
Revenue NY rev (1m)3.2%
Revenue NY rev (3m)2.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 9.13 | ||
| P/S | 0.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.7 | ||
| P/tB | 1.74 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.35
Fwd EY10.95%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 290.01% | ||
| Cap/Sales | 5.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | -0.01 |
F-Score3
WACC7.46%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-338%
EPS Next 2Y1.49%
EPS Next 3Y-6.52%
EPS Next 5Y2.74%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year13.31%
Revenue Next 2Y-8.22%
Revenue Next 3Y-7.29%
Revenue Next 5Y-5.76%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-278.15%
EBIT Next 3Y9.2%
EBIT Next 5Y11.92%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
Can you provide the valuation status for SAREPTA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
What is the profitability of SRPT stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
How financially healthy is SAREPTA THERAPEUTICS INC?
The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 3 / 10.